This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gallafent, J. H. Articles by Aboulafia, D. M. Search for Related Content PubMed PubMed Citation Articles by Gallafent, J. H. Articles by Aboulafia, D. M.

Profile of Patients With Kaposi's Sarcoma in the Era of Highly Active Antiretroviral Therapy

From the University of Washington, School of Medicine and Department of Epidemiology; Public Health—Seattle and King County, HIV/AIDS Epidemiology Program; and Virginia Mason Medical Center, Division of Hematology/Oncology, Seattle, WA

Address reprint requests to David M. Aboulafia, MD, University of Washington School of Medicine, Virginia Mason Medical Center, 1100 9th Ave, Seattle, WA 98111; e-mail: hemdma{at}vmmc.org

PURPOSE: Since the advent of highly active antiretroviral therapy (HAART), the incidence of Kaposi's sarcoma (KS) among AIDS patients has declined both nationwide and in King County, Washington. We sought to compare clinical parameters of patients diagnosed with KS in the pre-HAART (1990 to 1996) and HAART (1997 to 2002) eras.

METHODS: We used patient data abstracted from the Adult/Adolescent Spectrum of HIV-Related Diseases study of Public Health—Seattle and King County.

RESULTS: Patients diagnosed with KS in the HAART era (n = 40) were significantly more likely (P < .05) than pre–HAART-era KS patients (n = 366) to be diagnosed with alcohol problems (43% v 18%), noninjection drug use (45% v 18%), injection drug use (25% v 10%), psychosis (25% v 13%), and hypertension (13% v 2%). Although median CD4⁺ count and HIV-1 viral load at the time of KS diagnosis were not significantly different between the two groups, significantly fewer (P < .01) HAART-era KS patients developed opportunistic illnesses (OIs) during their follow-up. The risk of dying among KS patients diagnosed in the HAART era is significantly lower (P < .01) than for KS patients diagnosed in the pre-HAART era (hazard ratio, 0.24).

CONCLUSION: Although HAART-era KS patients in King County were as likely to have a depleted CD4⁺ cell count and high HIV-1 viral loads at the time of KS diagnosis as pre-HAART KS patients, they survived longer and fewer of them were diagnosed with other OIs. They also had an increased prevalence of substance abuse and mental illness, contributing to a dynamic and changing KS clinical profile.

Supported by the Medical Science Research Training Program at the University of Washington School of Medicine.

Presented in part as a poster at the 45th Annual Meeting of the American Society of Hematology, San Diego, CA, December 6-9, 2003, and in part as a poster at the 8th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, MD, April 29-30, 2004. Presented orally at the 2004 Western Student Medical Research Forum.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				T. Maurer, M. Ponte, and K. Leslie HIV-Associated Kaposi's Sarcoma with a High CD4 Count and a Low Viral Load N. Engl. J. Med., September 27, 2007; 357(13): 1352 - 1353. [Full Text] [PDF]

				S. Grabar, B. Abraham, A. Mahamat, P. Del Giudice, E. Rosenthal, and D. Costagliola Differential Impact of Combination Antiretroviral Therapy in Preventing Kaposi's Sarcoma With and Without Visceral Involvement J. Clin. Oncol., July 20, 2006; 24(21): 3408 - 3414. [Abstract] [Full Text] [PDF]

				M. Bower, D. Mazhar, and J. Stebbing Should Cervical Cancer Be an Acquired Immunodeficiency Syndrome-Defining Cancer? J. Clin. Oncol., June 1, 2006; 24(16): 2417 - 2419. [Full Text] [PDF]